astrazeneca oral glp 1 AstraZeneca's GLP-1 scored phase 2 wins, but no data yet In Potential $2B Deal, AstraZeneca
Description
In the present work, liraglutide was acutely administered and DNA was extracted from cecal content
Risk factors that might warrant consideration of medication adjustment include: Recent initiation or dose escalation of GLP-1 therapy Significant gastrointestinal symptoms (nausea, vomiting, early satiety) Maximum medication doses Known gastroparesis or other conditions affecting gastric emptying For patients where holding the medication is deemed appropriate, the duration should be individualized based on the specific medication, patient factors, and clinical judgment
PMID 40471562
Lv et al., 2014
Who Is This Drug Best For
ProFound Therapeutics ProFound Therapeutics is leveraging previously undiscovered human proteins to develop treatments for a wide range of diseases
